Outcomes and Treatments After Pembrolizumab in Non–Small Cell Lung Cancer

09 Apr 20264 min read4 viewsJournal Feed

GIST (Key Takeaways)

Rousseau A , Foulon S , Planchard D, et al. Outcomes and Treatments of Patients With Non–Small Cell Lung Cancer Who Received Pembrolizumab. JAMA Oncol.
Published online April 09, 2026. doi:10.1001/jamaoncol.2026.0669 Question What are the outcomes for patients with non–small cell lung cancer (NSCLC) after pembrolizumab discontinuation at 2 years? Findings In this cohort study of 1480 patients with NSCLC, the survival rate 48 months after discontinuation was 76.9%, and 387 patients (26.1%) received a subsequent therapy, which was mostly chemotherapy and radiotherapy.
Meaning The study results indicate that most patients were alive several years after immunotherapy cessation and immunotherapy rechallenge was uncommon. Importance Two years of immunotherapy is the standard treatment for most patients with advanced non–small cell lung cancer. However, little is known about postimmunotherapy therapeutic strategies.
Objective To describe subsequent treatments and outcomes after pembrolizumab discontinuation following 2 years of therapy.

Clinical Editorial

JAMA Oncology published a clinical update in Oncology on 09 Apr 2026.

The item focuses on Outcomes and Treatments of Patients With Non–Small Cell Lung Cancer Who Received Pembrolizumab.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Benmelstobart Plus Anlotinib Versus Pembrolizumab in First-Line PD-L1–Positive Advanced NSCLC (C

Oncology • 10 Mar 2026

Nat Rev OncRelated by Drugpembrolizumab

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer

Oncology • 17 Jun 2026

Br J CancerRelated by Drugpembrolizumab

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Oncology • 18 Apr 2026

ClinicalTrialsRelated by Drugpembrolizumab

Surgical Pembro +/- Olaparib w TMZ for rGBM

Oncology • 04 Mar 2026

Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study

Infectious Disease • 13 Jul 2026

JCORelated by Drugpembrolizumab

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP

Oncology • 14 Apr 2026

Feed Metadata

Source

JAMA Oncology

Outcomes and Treatments After Pembrolizumab in Non–Small Cell Lung Cancer

GIST (Key Takeaways)

Clinical Editorial

Source Reference

Related by Condition/Drug

Benmelstobart Plus Anlotinib Versus Pembrolizumab in First-Line PD-L1–Positive Advanced NSCLC (C

New standards and new&#xa0;constraints redefine treatment sequencing in platinum-resistant ovarian cancer

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Surgical Pembro +/- Olaparib w TMZ for rGBM

Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP

Outcomes and Treatments After Pembrolizumab in Non–Small Cell Lung Cancer

GIST (Key Takeaways)

Clinical Editorial

Source Reference

Related by Condition/Drug

Benmelstobart Plus Anlotinib Versus Pembrolizumab in First-Line PD-L1–Positive Advanced NSCLC (C

New standards and new&#xa0;constraints redefine treatment sequencing in platinum-resistant ovarian cancer

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Surgical Pembro +/- Olaparib w TMZ for rGBM

Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer